Novartis saw its profit margin expand in 2021 as operating expenses were kept in check while sales grew. However the pace of expansion was limited to the company’s proprietary medicines division. Sandoz, its generics business, had flat sales for the year as volume growth was more than offset by a decline in prices. In a statement on 2 February, Novartis said it is exploring several options for Sandoz, including a separation of the business. Further information is expected, at the latest, by the end of 2022.
